Phase 2 Trial Assesses c-Abl Inhibitor for Early Parkinson’s
In a landmark clinical advancement poised to reshape the therapeutic landscape of neurodegenerative disorders, researchers have unveiled compelling data on ...
In a landmark clinical advancement poised to reshape the therapeutic landscape of neurodegenerative disorders, researchers have unveiled compelling data on ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine